Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
AstraZeneca plans to invest $50B in US manufacturing and R&D by 2030, aiming for $80B revenue. This will create tens of thousands of jobs and enhance drug production capabilities.
AstraZeneca's Baxdrostat shows significant promise in treating uncontrolled hypertension, marking a major advancement in cardiovascular medicine.
Discover AstraZeneca's total voting rights and regulatory compliance in the July 2025 report, vital for shareholders and investor relations.
Explore AstraZeneca's strategic collaboration with CSPC Pharmaceuticals, focusing on AI-enabled drug discovery for chronic diseases, with potential milestones of over $5 billion.
Explore AstraZeneca PLC's June 2025 report detailing an insider transaction by CFO Aradhana Sarin, showcasing corporate governance through a charitable gift of shares.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.
Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.
AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.